Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance

By Kari R. Fischer, A. Durrans, Sharrell B Lee, J. Sheng, Fuhai Li, Stephen T. C. Wong, Hyejin Choi, Tina El Rayes, S. Ryu, Juliane S. Troeger and 5 more. Nature, 2015

1,651 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/235381833279d80b9ac227ac1c20f00812872165

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Jing Yang
2. K. Yeung
3. Yibin Kang
4. Andrew J. Ewald
5. Yuhe Huang
6. Raghu Kalluri
7. Xiawei Wei
8. Weiqi Hong

In Oncology

1. K. Yeung
2. Raghu Kalluri
3. Yibin Kang
4. J. Shim
5. Wei Dang Lu
6. Andrew J. Ewald
7. Yuhe Huang
8. Jing Yang

Citations in the corpus

• Systems Biology of Cancer Metastasis (2019, background): “…with, stroma, escaping immune surveillance by inhibiting or co-opting their anti-tumorigenic processes, evading and modulating the tissue microenvironment, and evolving resistance to therapeutic intervention(Fischer et al., 2015; Kalluri, 2016; Li et al., 2016b; Massague and Obenauf, 2016).”
• Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer (2016, background): “[28] established an EMT lineage-tracing system to monitor reversible and transient EMT process in mice.”
• EMERGING BIOLOGICAL PRINCIPLES OF METASTASIS (2017, neutral): “Two studies have recently undertaken to refute the essential role of the EMT program in the process of metastasis (Fischer et al., 2015; Zheng et al., 2015).”
• Epithelial-mesenchymal plasticity in cancer progression and metastasis (2019, background): “More recently, two separate studies using genetically engineered mouse models demonstrate that primary and metastatic tumor cells become more resistant to chemotherapeutic drugs in an EMT-dependent manner in both breast and pancreatic cancers (Fischer et al., 2015; Zheng et al., 2015).”
• Dynamic EMT: a multi‐tool for tumor progression (2021, neutral): “Moreover, Bornes and colleagues demonstrated that Fsp1-Cre mediated lineage tracing as used by Fischer et al (2015) is incapable in detecting the majority of disseminating cells that are in a partial/hybrid EMT state (Fischer et al , 2015; Bornes et al , 2019).”
• Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors (2017, neutral): “A gene was said to be highly expressed in any given cell if its expression was greater than log10 (50) and also greater than its own median non-pseudocounted expression value across all cells.”
• Epithelial–mesenchymal transition in tumor metastasis (2016, background): “However, no enrichment of GFP-positive tumor cells was observed in the resulting distant metastasis lesions (Fischer et al., 2015).”
• Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “Furthermore, several other potential sources of CAFs have been identified, such as epithelial cells [63, 64], pericytes [65], monocytes [66], endothelial cells [67] and smooth muscle cells [68].”
• Drug resistance and combating drug resistance in cancer (2019, background): “Fischer et al.([122]) reported that EMT promotes resistance to apoptosis induction activated by drug cyclophosphamide in an EMT lineage-tracing mouse system.”